Assessment of the genotoxicity of atenolol in human peripheral blood lymphocytes: correlation between chromosomal fragility and content of micronuclei

Mutat Res. 2010 Jan;695(1-2):46-54. doi: 10.1016/j.mrgentox.2009.02.015. Epub 2009 Nov 20.

Abstract

The antihypertensive drug atenolol was found to induce chromosome loss, detected as micronuclei in the peripheral lymphocytes of treated patients. The fundamental question which chromosomes the micronuclei were derived from remains to be answered. Analysis of structural chromosomal aberrations (CAs) and expression of fragile sites (FS) were pursued in this study. They revealed a significantly higher incidence of chromosomal aberrations (chromatid and chromosome breaks) in patients compared with controls, where 10 FS emerged as specific. Also, the band 17q12-21, where known fragile sites have not been reported, was only expressed in atenolol-treated patients. Fluorescence in situ hybridization using chromosome-specific probes revealed the preferential involvement of chromosomes 7, 11, 17 and X in the micronuclei (MN) of patients. The results also suggest a correlation between chromosomal fragility and content of MN, and support the findings for a linkage between hypertension and a locus on chromosome 17.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antihypertensive Agents / toxicity*
  • Atenolol / toxicity*
  • Case-Control Studies
  • Chromosome Fragile Sites
  • Chromosome Fragility / drug effects*
  • Chromosomes, Human, Pair 17 / genetics
  • DNA Damage* / drug effects
  • Female
  • Humans
  • Hypertension / drug therapy*
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Lymphocytes / drug effects*
  • Male
  • Micronuclei, Chromosome-Defective / drug effects*
  • Micronucleus Tests
  • Middle Aged

Substances

  • Antihypertensive Agents
  • Atenolol